<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040646</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2805</org_study_id>
    <nct_id>NCT05040646</nct_id>
  </id_info>
  <brief_title>The Development of a Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer</brief_title>
  <official_title>Study Protocol - The Development of a Novel Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer: An International Delphi Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to develop an international tool that can be used to assess burden&#xD;
      of disease in patients enrolled in the W&amp;W program for rectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The watch-and-wait (W&amp;W) strategy in rectal cancer is a organ-sparing treatment option, where&#xD;
      patients with a clinical complete response (cCR) after neoadjuvant chemo(radio)therapy, do&#xD;
      not undergo surgery but instead follow a strict follow-up scheme. The goal of the W&amp;W&#xD;
      strategy is to preserve the rectum and thereby retain functional outcomes (FO) (e.g.&#xD;
      gastro-intestinal, urinary, sexual) and improve quality of life (QoL).&#xD;
&#xD;
      Patient Reported Outcome Measures (PROMs) reflect the patients' evaluation of their symptoms,&#xD;
      FO and QoL. In the W&amp;W program various PROMs (e.g. EORTC-CR29/C30, LARS, SF-36) are used to&#xD;
      assess the these different outcomes. However, most of the PROMs used are developed and&#xD;
      validated in a surgical patient group. So the relevance and usefulness of these PROMs may be&#xD;
      limited in W&amp;W patients.&#xD;
&#xD;
      For use in clinical practice, a short PROM would support follow-up care as it provides a&#xD;
      clear overview of the problems W&amp;W patients experience.&#xD;
&#xD;
      This paper describes the protocol for the development of an international tool that can be&#xD;
      used to assess burden of disease in patients enrolled in the W&amp;W program for rectal cancer.&#xD;
      We will use the Delphi methodology to reach consensus about items that should be included in&#xD;
      the novel tool. The aim of this tool is to improve direct patient care during the entire&#xD;
      Watch-and-Wait program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Consensus in / Important outcome</measure>
    <time_frame>between 3 months and 5 years of follow up</time_frame>
    <description>&gt;70% of the participants in each panel rating the outcome '7-9' OR &lt;70% of the clinicians and (clinical) researchers rating the outcome '7-9' but an average patient rating of &gt;7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Consensus in / No important outcome</measure>
    <time_frame>between 3 months and 5 years of follow up</time_frame>
    <description>&lt;70% of the clinicians and (clinical) researchers rating the outcome '7-9' AND an average patient rating of &lt;7</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients who follow the watch-and-wait program for rectal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experts</arm_group_label>
    <description>Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Delphi exercise</intervention_name>
    <description>During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W&amp;W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.&#xD;
After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached.</description>
    <arm_group_label>Experts</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of both patients and experts (surgeons, radiotherapist,&#xD;
        medical oncologist and other medical personnel) who are involved in the watch-and-wait&#xD;
        program for rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have to be treated with neoadjuvant (chemo)radiotherapy&#xD;
&#xD;
          -  Patients are included into the Watch-and-Wait program&#xD;
&#xD;
          -  Experts involved in the treatment of rectal cancer&#xD;
&#xD;
          -  Experts involved in the Watch-and-Wait program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regrowth of disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie Breukink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Pennings, MD</last_name>
    <phone>+31 43 38 82449</phone>
    <email>a.pennings@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie Breukink, MD, PhD</last_name>
    <phone>+31 43 387 2807</phone>
    <email>s.breukink@mumc.nl</email>
  </overall_contact_backup>
  <reference>
    <citation>Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J, Black N. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient Rep Outcomes. 2018 Sep 15;2:42. doi: 10.1186/s41687-018-0061-6. eCollection 2018 Dec. Review.</citation>
    <PMID>30294712</PMID>
  </reference>
  <reference>
    <citation>Ishaque S, Karnon J, Chen G, Nair R, Salter AB. A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs). Qual Life Res. 2019 Mar;28(3):567-592. doi: 10.1007/s11136-018-2016-z. Epub 2018 Oct 3.</citation>
    <PMID>30284183</PMID>
  </reference>
  <reference>
    <citation>Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013 Jan 28;346:f167. doi: 10.1136/bmj.f167.</citation>
    <PMID>23358487</PMID>
  </reference>
  <reference>
    <citation>Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I. Increasing response rates to postal questionnaires: systematic review. BMJ. 2002 May 18;324(7347):1183. Review.</citation>
    <PMID>12016181</PMID>
  </reference>
  <reference>
    <citation>Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewé KW, Buijsen J, Beets GL. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011 Dec 10;29(35):4633-40. doi: 10.1200/JCO.2011.37.7176. Epub 2011 Nov 7.</citation>
    <PMID>22067400</PMID>
  </reference>
  <reference>
    <citation>van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018 Jun 23;391(10139):2537-2545. doi: 10.1016/S0140-6736(18)31078-X.</citation>
    <PMID>29976470</PMID>
  </reference>
  <reference>
    <citation>Habr-Gama A, São Julião GP, Fernandez LM, Vailati BB, Andrade A, Araújo SEA, Gama-Rodrigues J, Perez RO. Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! Dis Colon Rectum. 2019 Jul;62(7):802-808. doi: 10.1097/DCR.0000000000001338.</citation>
    <PMID>31188180</PMID>
  </reference>
  <reference>
    <citation>Hsu, C. and B. Sandford, The Delphi technique: making sense of consensus-Practical assessment, research &amp; evaluation. Pract Assessment. Res Eval, 2007. 12.</citation>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Watch-and-wait</keyword>
  <keyword>Organ-preserving treatment method</keyword>
  <keyword>Functional outcomes</keyword>
  <keyword>Patient reported outcome measures</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Delphi exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

